No conflicts of interest were declared.
CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges
Article first published online: 20 NOV 2012
Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
The Journal of Pathology
Volume 229, Issue 3, pages 355–378, February 2013
How to Cite
Grosse-Gehling, P., Fargeas, C. A., Dittfeld, C., Garbe, Y., Alison, M. R., Corbeil, D. and Kunz-Schughart, L. A. (2013), CD133 as a biomarker for putative cancer stem cells in solid tumours: limitations, problems and challenges. J. Pathol., 229: 355–378. doi: 10.1002/path.4086
- Issue published online: 25 JAN 2013
- Article first published online: 20 NOV 2012
- Accepted manuscript online: 16 AUG 2012 04:57AM EST
- Manuscript Accepted: 4 AUG 2012
- Manuscript Revised: 30 JUL 2012
- Manuscript Received: 29 JUN 2012
- post-translational modification;
- cancer stem cells;
The cancer stem cell (CSC) hypothesis, despite the limitations of the currently available models and assays, has ushered in a new era of excitement in cancer research. The development of novel strategies for anti-tumour therapy relies on the use of biomarkers to identify, enrich, and/or isolate the cell population(s) of interest. In this context, various cell characteristics and antigen expression profiles are discussed as surrogate markers. The cell surface expression of the human prominin-1 (CD133) antigen, in particular of the AC133 epitope, is among those that have been most frequently studied in solid cancers, although no mechanism has yet been proposed to link CD133 expression with the CSC phenotype. Some inconsistencies between published data can be ascribed to different analytical tools as well as methodological limitations and pitfalls, highlighted in the present review. Therefore, a comprehensive overview on the current state of knowledge in this growing and exciting field with an emphasis on the most recent studies is presented. We highlight the link between the tumour microenvironment, tumour cell plasticity, and CD133 expression, and evaluate the utility of CD133 expression as a prognostic marker. Copyright © 2012 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.